| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.073 | 0.2 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.28 | 0.2 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |